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ABSTRACT: Idiosyncratic drug-induced liver injury (iDILI), which is
rare and often recognized only late in drug development, poses a major
public health concern and impediment to drug development due to its
high rate of morbidity and mortality. The mechanisms of DILI are not
completely understood; both non-immune- and immune-mediated
mechanisms have been proposed. Non-immune-mediated mechanisms
including direct damage to hepatocytes, mitochondrial toxicity,
interference with transporters, and alteration of bile ducts are well-
known to be associated with drugs such as acetaminophen and diclofenac;
whereas immune-mediated mechanisms involving activation of both
adaptive and innate immune cells and the interactions of these cells with
parenchymal cells have been proposed. The chemical signals involved in
activation of both innate and adaptive immune responses are discussed with respect to recent scientific advances. In addition,
the immunological signals including cytokine and chemokines that are involved in promoting liver injury are also reviewed.
Finally, we discuss how liver tolerance and regeneration can have profound impact on the pathogenesis of iDILI. Continuous
research in developing in vitro systems incorporating immune cells with liver cells and animal models with impaired liver
tolerance will provide an opportunity for improved prediction and prevention of immune-mediated iDILI.
1. INTRODUCTION
Drug-induced liver injury (DILI) is one of the most common
causes of clinical trial failures of new therapeutic agents (33%)
and post-marketing withdrawals.1 In particular, idiosyncratic
drug-induced liver injury (iDILI), which is rare and often only
recognized late in drug development, poses a major clinical
challenge due to its high rate of morbidity and mortality coupled
with its unpredictable nature. iDILI can be characterized as
hepatocellular, cholestatic, or mixed type of liver injury
depending on the ratio of alanine aminotransferase to alkaline
phosphatase relative to their respective upper limits of normal.2
Antibiotics and nonsteroidal anti-inflammatory drugs
(NSAIDs) namely amoxicillin-clavulanate, flucloxacillin, diclo-
fenac, and isoniazid are most often associated with iDILI.3
Under basal conditions, the liver not only is capable of regulating
immune responses against pathogens from the gut and the
circulatory system but also maintaining a tolerogenic environ-
ment. Moreover, the liver is a unique organ with an
extraordinary capacity to regenerate after damage. The
regeneration is surprisingly fast and plays a pivotal role in
maintaining body homeostasis.4 However, impaired liver
tolerance and insufficient regeneration and repair, for example,
during infection, inflammation, and inhibition of immune
modulators, can lead to the activation of immune cells.5,6
Following the initial immune activation, additional mechanisms
including transporter inhibition, oxidative stress, and the
potential involvement of the innate immune system can further
amplify or reduce the injury, thereby determining the
progression and severity of DILI. Therefore, understanding
the complex interactions between immune cells and the local
parenchymal or nonparenchymal cells in the liver, particularly
those factors that determine tolerance and immunity, will inform
the various immunological mechanisms of DILI.
Although the mechanisms underlying the pathogenesis of
iDILI are not completely understood, many cases show features
of immune-mediated reactions such as the presence of a rash,
fever, eosinophilia, and a rapid positive rechallenge in the clinic.
The detection of antibodies directed against native or drug-
modified hepatic proteins in DILI patients,7 the infiltration of
cytotoxic CD8+ T-cells in the liver,8 and circulating drug-
specific T-cells9−11 in patients support immune-based mecha-
nisms. The association between specific alleles of human
leukocyte antigen (HLA) class I and II and susceptibility to
liver injury further supports the involvement of adaptive
immunity in iDILI. A growing number of HLA alleles have
been identified to be associated with drugs including amoxicillin-
clavulanate,12 ticlopidine,13 ximelagatran,14 flucloxacillin,15
lumiracoxib,16 and lapatinib.17 Despite intensive research in
this field, the precise cascade events that lead to the activation of
the immune system and how this manifests into liver injury
remain to be fully defined. This review focuses on the chemical
signals that activate immune cells and the molecular pathways
that promote liver injury.
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2. IMMUNOLOGICAL FUNCTIONS WITHIN THE LIVER
2.1. The Anatomical Structure and Physiological
Functions of the Liver. The liver is the largest solid organ
in the body and is critical to metabolic processes and immune
functions (Figure 1). Lobules comprised of canaliculi flowing
toward the common bile duct exist alongside small sinusoids
flowing from branches of the hepatic portal vein and hepatic
artery to a “central” vein, a branch of the hepatic vein.18 Through
this network, all of the blood flow from the gastrointestinal tract
passes through the sinusoids, exiting into the central vein. The
liver contains a mixture of cell types, including parenchymal
cells, that is, hepatocytes, and multiple nonparenchymal cells
located around the sinusoids, creating a unique network for
cellular communication. Hepatocytes perform the majority of
hepatic metabolic functions, which are highly regulated by
substances released from the neighboring nonparenchymal cells
such as liver sinusoidal endothelial cells (LSECs), biliary
epithelial cells (cholangiocytes), hepatic stellate cells (HSCs),
Figure 1. Structure of the liver. (A) The liver is a large organ supplied by multiple arteries and veins. Oxygenated blood is supplied to the liver via the
hepatic artery, a branch of the aorta. It exits via the hepatic vein to the inferior vena cava. The portal vein supplies blood from the digestive system for
the liver to undertake its primary functions of metabolism, detoxification, and others. (B) Close up schematic of the lobules of the liver. Blood enters
the lobules through branches of the portal vein and the hepatic artery where they aremixed in the sinusoids. Excretion products are transported into the
bile canaliculi where they enter the bile duct and are subsequently excreted into the duodenum. Resident immune cells, such as KCs and T-cells, are
present in the sinusoids of the liver.
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and large populations of immune cells.19 Apart from resident
innate immune cells such as Kupffer cells (KCs), dendritic cells
(DCs), and natural killer cells (NKs), and intrahepatic
lymphocytes (natural killer T-cells, CD4+ and CD8+ T-cells),
the unique vascularization of the liver also allows the rapid
recruitment of circulating leukocytes during tissue damage and
inflammation. The co-residence of these immune cells in the
liver creates a unique environment that regulates liver
homeostasis to maintain a delicate balance between tolerance
and immunity.
2.2. The Role of the Innate Immune System in DILI.
Within the liver, innate immune cells including KCs, NKs,
neutrophils, DCs, and NK T-cells are critical for maintaining
liver homeostasis by inducing both immunogenic and
tolerogenic immune responses. However, the precise role of
each innate immune cell in the pathogenesis of DILI remains ill
defined. It has been shown that innate immunity plays an
important role in responding to drug-induced stress. The factors
that activate innate immune cells are not completely understood.
It has been hypothesized that reactive metabolites, hepatocytes-
derived exosomes,20,21 or danger-associated molecular pattern
(DAMP) molecules released by apoptotic and necrotic cells can
activate these cells. Especially, DAMPs including high mobility
group box 1 (HMGB1) protein, ATP, mitochondrial DNA,
nuclear DNA fragments, RNA, purines, uric acid, heat-shock
proteins (HSPs), and bile acids have been shown to activate
KCs, neutrophils, and DCs via toll-like receptors (TLRs).
DAMPs released by necrotic hepatocytes due to overdoses of
acetaminophen (APAP) can activate KCs and neutrophils,
which may enhance inflammation by secreting various pro-
inflammatory cytokines.22 The release of HSPs has also been
shown to mature DCs and promote the secretion of pro-
inflammatory cytokines through TLR activation.23 HMGB1,
forming relatively stable complexes with promiscuous sub-
strates, can promote the maturation of DCs through TLR-4-
dependent signaling. Primary human hepatocytes cultured with
SMX-NO and flucloxacillin resulted in a drug-specific and
concentration-dependent release of HMGB1. Culturing DCs
with HMGB1 conditioned medium resulted in the secretion of
IL-1α, IL-1β, TNF-α, and IL-6, leading to the enhanced priming
of naiv̈e T-cells.24 Reactive acyl glucuronide metabolite of
diclofenac has been shown to activate neutrophils in vitro and in
vivo, and the activated neutrophils partly contributed to the
pathogenesis of diclofenac-induced acute liver injury.25
Activated innate immune cells can in turn produce reactive
oxygen species and other inflammatory mediators, perpetuating
further inflammation (Figure 2). Due to the complex and
overlapping inflammatory mediators released by these cells and
many of the experimental techniques used to inhibit a cell type, it
has been difficult to define the contribution of these cells to
iDILI and how the innate and adaptive immune systems interact
in the liver of a susceptible patient. It should be noted that
activation of innate immunity does not necessarily lead to
adaptive immune responses. Overwhelmed innate immunity
that resulted in extensive liver injury may activate the regulatory
pathways, leading to inhibition of adaptive immune responses to
prevent further injury. Indeed, although extensive protein
adducts were formed following APAP overdoses, the lack of
APAP-specific lymphocytes could be partially due to the
immunosuppression following APAP hepatotoxicity.26 How-
ever, activation of innate immune system is a prerequisite for
adaptive immunity.
2.3. The Role of Adaptive Immunity in DILI. Adaptive
immunity including both humoral and cellular immune
responses play an important role in immune-mediated iDILI.
Humoral immune responses, mediated primarily by antibodies,
may cause hepatotoxicity through either complement activation
or antibody-dependent cytotoxicity. Cellular immune responses
involve activation of antigen-specific T lymphocytes, followed
by subsequent T-cell-mediated cytotoxicity. Although the exact
Figure 2. Interactions between the innate and adaptive immune cells and liver cells. Damaged liver cells can release DAMPs, which are important in
activating innate immune cells. The activated innate immune cells can either release cytokines or present drug-associated antigens, leading to activation
of adaptive immune cells. The cytotoxic T-cells can kill the hepatocytes, leading to liver injury when the liver regenerative capacity is impaired.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
C
role of humoral immunity in iDILI remains undefined, both
antidrug antibodies (ADAs) and autoantibodies detected in the
sera of iDILI patients have been shown to induce significant
cytotoxicity to hepatocytes. For example, IgG3 anti-isoniazid
antibodies and anticytochrome P450 antibodies were detected
in the sera of patients with isoniazid DILI. These antibodies
were found to be associated with a Th1-type immune response
that may play a pathogenic role in isoniazid DILI.7,27 Moreover,
ADA formation has been amajor limitation for the clinical use of
therapeutic proteins (TPs), such as the antitumor necrosis factor
(TNF) superfamily including infliximab, adalimumab, and
recombinant human Apo2L/TRAIL.28,29 ADAs directed against
TPs are believed to contribute to the hepatotoxicity through the
formation of a drug/ADA immune complex, which activates the
complement cascade and promotes B-cell maturation.30
A growing number of cases have shown that both circulating
and liver resident lymphocytes are involved in DILI. IFN-γ and
granzyme-B secreting flucloxacillin-specific T-cells have been
identified in the blood of patients with flucloxacillin-induced
liver injury.9 Also, T-cells isolated from patients with
amoxicillin/clavulanic acid and isoniazid DILI have been
shown to proliferate and secrete IFN-γ in response to drug
treatment.10,11 Although the identification of peripheral drug-
specific T-cells in DILI patients provided strong evidence for the
involvement of the adaptive immune system, the precise
molecular mechanisms whereby these peripheral drug-specific
T-cells cause injury to the liver remain unknown. It is worth
noting that the resident lymphocytes in the liver are phenotypi-
cally different from those in peripheral blood, in that they
generally lack the cytotoxic functions. These cytotoxic CD8+
cells either migrate from peripheral blood or are expanded
locally upon antigen stimulation and can attack and/or damage
hepatocytes/cholangiocytes, leading to liver injury. Apart from
CD8+ T-cells, Th17 cells have also been implicated in DILI in
mouse models.31
Importantly, a number of HLA class I and II alleles have been
shown to play a significant role in iDILI susceptibility, indicating
the involvement of adaptive immune responses in the patho-
genesis of iDILI. Details of HLA associations with specific drugs
can be found in recent reviews.32−34 These discoveries provided
mechanistic insight into the activation of adaptive immunity and
paved the way for predicting iDILI in certain patient
populations. Although almost all associations have high negative
predictive values, the low incidence of iDILI leads to a low
positive predictive value for the majority of iDILI-associated
HLA alleles. For example, strong association was observed
between HLA-B*57:01 and flucloxacillin iDILI, however, the
low positive predictive value of this association (0.12%) makes
the prospective screening tests for identification of patients at
risk of flucloxacillin iDILI economically unpractical.35 While
HLA associations may not provide any clinical value in
predicting DILI per se, they may be one of several factors
which can influence drug-T-cell interactions at the molecular
level, which may potentially lead to different clinical outcomes.
The common associations of some haplotypes with structurally
unrelated drugs are extremely interesting, for example, the
association of HLA-DRB1*15:01-DQB1*06:02 haplotype with
amoxicillin-clavulanate12 and lumiracoxib16 DILI and HLA-
B*57:01 with flucloxacillin and pazopanib36 DILI. Abacavir, a
retroviral treatment used in HIV infection, is also strongly
associated with the carriage of HLA-B*57:01. Abacavir
hypersensitivity syndrome (AHS) occurs in 2−5% of patients,
resulting in fever, rash, nausea, and vomiting. A number of
studies identified the genetic association between abacavir and
HLA-B*57:01, giving a positive predictive value of 48% and a
negative predictive value of 100%. Carriage of HLA-B*57:01
results in a 48% chance of developing AHS, while 100% of cases
are from patients carrying the allele. While all three share the
same genetic predisposition, it is not fully understood why
flucloxacillin and pazopanib result in DILI when abacavir
manifests as a skin reaction. Furthermore, abacavir has a much
stronger association, resulting in 1 in 2 HLA-B*57:01 carriers
developing AHS. This is in contrast to 1 in 1000 carriers
developing flucloxacillin iDILI.15 The strong association of
abacavir with HLA-B*57:01 could be related to the unique
binding of abacavir to the F pocket of the peptide binding
groove, which has not been observed with any other drug
molecules. Due to the structural difference, these drugs may
bind differently to the peptide binding groove, leading to altered
presentation of drug associated self-peptides, which can
potentially result in autoimmune-like reactions.
3. CHEMICAL SIGNALS FOR THE ACTIVATION OF
DRUG-SPECIFIC T-CELL RESPONSES
3.1. Mechanisms of T-Cell Activation. Activation of naiv̈e
T-cells generally requires multiple signals presented by antigen
presenting cells (APCs). The first signal, which is essential for
initiating T-cell activation, is the interaction between T-cell
receptors (TCRs) and antigenic peptides presented by HLA
molecules on the surface of APCs. The second signal is the
interaction between the co-stimulatory molecules on T-cells
(e.g., CD28) and their ligands. The third signal, which
suppresses T-cell activation, is the interactions between the
coinhibitory molecules on the T-cells and their ligands on APCs,
for example, programmed cell death protein 1 (PD-1) and PD-
ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated
protein 4 (CTLA4) and CD86/CD80. In addition, other signals
including danger signals, cytokines and chemokines may also
influence the outcome of T-cell activation.
Lymphocytes can be activated by drugs/metabolites through
multiple mechanisms. Covalent binding of drugs/metabolites to
proteins, which are processed and presented as drug-modified
peptides by APCs, can stimulate drug-specific T-cells (hapten
hypothesis, Figure 3). Alternatively, T-cells can be activated by
direct interactions of drugs (metabolites) with immune cells (PI
hypothesis) or even drug-altered self-peptides (altered peptides
hypothesis). Recent studies revealed the heterogeneity of drug-
specific T-cells from patients with DILI that can recognize both
drug-modified proteins and the drug itself, indicating multiple
mechanisms could be involved.37 Advanced structural biology
coupled with proteomic techniques has allowed investigation of
the detailed interactions between antigens and immune
receptors, however, how activated drug-specific immune cells
induce liver injury has still not been fully elucidated
3.2. Drug Protein Conjugates As Potential Antigens.
Reactive drugs such as β-lactam antibiotics and covalent tyrosine
kinase inhibitors, and reactive metabolites (RMs), can
covalently bind to macromolecules. Particularly, RMs that
have extremely short half-lives or great affinity toward proteins
may preferentially bind to intracellular proteins. The resulted
drug protein conjugates can induce either drug-specific antibody
or T-cell responses, leading to unwanted immunological
reactions. Characterization of the precise structure of epitopes
formed on proteins is essential for understanding the interaction
between drugs and immune receptors, thus providing insights
into both the efficacy and safety of drug design. The emergence
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of sensitive bioanalytical and proteomic techniques has allowed
for a more precise identification of reactive metabolites and their
protein targets in both in vitro systems and in vivo (Figure 4).
Nowadays, screening and characterization of RM formation of
lead compounds during early drug discovery have been well
established. Because of the high chemical reactivity, trapping
agents including glutathione (GSH), cyanide, and amino acids
are commonly used to detect them readily in vitro. Owing to the
high sensitivity, LC-MS-basedmethods have been developed for
rapid screening of RM formation in complex matrices, while
NMR can be used for the absolute structural elucidation (Figure
4A). Multiple MS scan methods including the neutral loss,
precursor ion, and multiple reaction monitoring scans have been
traditionally used for characterization of GSH conjugates
formed by RMs.38 A recent study using a high-resolution MS
platform coupled with polarity switching has enabled rapid
screening and characterization of GSH-trapped RMs formed in
liver microsomes and hepatocytes.39 The structural elucidation
of trapped-RMs will undoubtedly provide insights into the
mechanisms of how protein adducts are formed. However, not
all RMs can be trapped with common trapping agents. Both
peptide-based trapping agents and model proteins such as GSH
S-transferase π and human serum albumin (HSA) that contain
multiple reactive nucleophilic residues have also been used to
map the global reactivity of RMs.40,41 It should be noted that the
formation of reactive metabolites does not necessarily lead to
toxicity, and extensive safety evaluation is required to determine
whether or not a compound that forms RMs should progress
through drug development.42
HSA has been identified as the major target for many reactive
drugs. For example, circulating HSA adducts formed by a
number of β-lactams were detected in the blood of patients
taking β-lactam antibiotics.43−45 These adducts have been
shown to activate both ADAs and drug-specific T-cells. Cross-
reactive ADAs and T-cells are common between penicillins due
to the conserved thiazolidine ring across the family of penicillins.
However, ADAs and T-cells that recognize the side chains of
penicillins are highly specific. In recent years, covalent drugs
have been developed for the treatment of cancer or hepatitis C
infections (e.g., ibrutinib and afatinib).46 These drugs can
covalently bind to cysteine residues in a number of tyrosine
kinases and display great clinical efficacy against cancer with
mutations. For example, afatinib is capable of forming Michael
adducts with cysteine residues within the catalytic sites of EGFR
(Cys797), HER2 (Cys805), and HER4 (Cys803).47 Despite
promising efficacy across a broad range of disease, there have
been great concerns that covalent drugs might cause potential
off-target toxicity. Rare but severe livery injury has been reported
to be associated with the use of ibrutinib and afatinib. Although
the exact mechanisms of the liver injury are not fully understood,
hepatocellular injury caused by lymphocytes infiltrate and
additional canalicular cholestasis suggests an immune mecha-
nism.48,49 How these drugs activate the immune system remains
unknown, however, covalent binding to off-target proteins to
form neoantigens could partly contribute to the immune-
mediated liver injury. Mass spectrometric (MS) analysis of
ibrutinib-modified HSA revealed that ibrutinib formed lysine
adducts (K190) viaMichael addition with lysine attacking the β-
carbon of the amide moiety.50 Whether and how ibrutinib-HSA
adducts contribute to the observed toxicity require further
investigation. However, ibrutinib was shown to irreversibly bind
to Cys424 in interleukin-2-inducible kinase, leading to
inhibition of downstream activation of Th2-polarized CD4+
T-cells in vitro and in vivo.51 Recent studies on covalent drugs
have focused on identification of both target and off-target
proteins to improve the efficacy, thereby reducing the toxicity
associated with this class of drugs. Novel chemical proteomic
methods to globally map the reactivity of functional cysteines in
proteomes have enabled accelerated identification of novel
protein targets and binding sites for kinase inhibitors.52−54 For
example, THZ1, a cyclin-dependent kinase inhibitor, also bound
to Cys840 on PKN3.54 Osimertinib, the third-generation
T790M-EGFR inhibitor, was found to react with multiple
cathepsins in cells and animal models due to the accumulation of
the drug in lysosomes.
HSA is also a target for many RMs because of its high
abundance in the liver. Both phase I and phase II metabolites
have been shown to form HSA adducts in in vitro system and in
vivo. A classic example of reactive phase I metabolites is NAPQI
formed by APAP. APAP protein adducts were detected even at
therapeutic doses, however, overdose resulted in extensive
covalent binding to proteins that may contribute to hepatotox-
icity.55,56 The levels of APAP protein adducts in patients with
acute liver failure (ALF) correlated well with the severity of
toxicity, supporting their use as specific biomarkers for APAP
toxicity in patients with ALF.57 However, the role of APAP-HSA
adducts in the activation of adaptive immunity remains
undefined. It should be emphasized that drugs with aniline
structural alerts, including lapatinib, diclofenac, nevirapine
(NVP), and amodiaquine, can all form HSA adducts through
the formation of quinone imine intermediates. Both ADAs and
drug-specific T-cells may contribute to liver injury associated
with these drugs. A number of phase II metabolites have also
been shown to form protein adducts both in vitro and in vivo.
NVP was shown to form protein adducts in the liver through its
phase II metabolite, NVP-12-sulfate.58 In addition, many
carboxylic acid-containing drugs such as NSAIDs can form
protein adducts through the reactive β-1-O-acyl glucuronides
Figure 3. Interactions between the peptide, MHC, drug, and TCR
follow three different hypotheses.MHC class Imolecules are comprised
of three α chains and a β-2-microglobulin subunit. Peptides are
presented in the binding groove located between two of the α chains.
(A) The drug interacts noncovalently with the peptide, MHC, and the
TCR. (B) The drug covalently binds to the peptide presenting a neo-
antigen to the TCR. (C) The drug interacts with the MHC, altering the
conformation of the peptide binding groove to accommodate nondrug-
modified neo-antigens. In all cases, these lead to T-cell activation and
subsequent cytokine release.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
E
(AGs). Two distinct types of adducts could be formed:
transacylation adducts through direct reactions with certain
amino acid residues on proteins, such as lysine, cysteine, and
arginine. Alternatively, a Schiff base adduct retaining the
glucuronide moiety could be formed through the reaction of
isomeric glucuronides with amine nucleophiles followed by an
Amadori rearrangement.59,60 ADAs against acylation adducts
have been detected in patients with liver injury, however, it
remains unknown whether acyl glucuronides are exclusively
responsible for antibody response in humans, as acylation
adducts could be formed through other pathways (e.g.,
Coenzyme A pathway). Interestingly, the AG of diclofenac,
and many other carboxylic acid-containing NSAIDs, has been
found to selectively bind to several proteins located on the apical
(bile canaliculi) domain of the hepatocyte plasma membrane.61
These drug-modified proteins may be responsible for the
accumulation of CD8+ T-cells around the bile ducts, which may
contribute to the cholestasis associated with many NSAIDs.
3.3. Antigenic Peptide Presentation. T-cell activation is
mediated through the interactions between the TCR and HLA-
peptide complex displayed by APCs. However, for the majority
of drugs, how drug molecules/metabolites are incorporated into
the HLA-peptide complex for T-cell recognition remains
undefined. Recently, advanced immunopeptidomic analysis of
HLA-peptide complexes eluted from APCs (Figure 4B) has
enabled the identification of thousands of peptides naturally
presented on the cell surface by HLA molecules. Coupled with
X-ray crystallographic analysis of HLA peptide complexes,
Figure 4.Characterization of drug associated antigens. (A) Drug metabolism in the liver leads to the formation of both stable and reactive metabolites;
these metabolites can be characterized by advanced bioanalytical techniques including LC-MS/MS and NMR. Drug protein adducts can be
characterized by immuno-histochemistry or Western blots using ADAs; the precise structure of epitopes can be determined by LC-MS/MS analysis.
(B) Drug associated antigenic peptides presented by specific HLA molecules can be characterized using immunopeptidomic studies; peptides are
eluted from antigen presenting cells using immuno-affinity columns, followed by HPLC purification and LC/MS/MS analysis.
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immunopeptidomics has provided new insights into the
mechanisms of immune-mediated disease. For example, recent
studies have shown that abacavir interacts with the peptide
binding cleft of HLA-B*57:01, altering the shape and chemistry
of the HLA molecule and the array of peptides that bind.62−64
Further structural elucidation of the drug peptide-HLA complex
revealed that abacavir bound noncovalently in the vicinity of the
F pocket of the HLA binding groove. Up to a thousand abacavir
unique HLA binding peptides were identified, however, their
contribution to the CD8+ T-cell response seen in abacavir
hypersensitive patients is yet to be defined.
In terms of activation of drug-specific CD8+ T-cells involved
in liver injury, it is possible that reactive metabolites formed
within the liver can covalently bind to intracellular proteins
followed by presentation of drug-modified peptides or directly
bind to peptide-HLA complexes and the HLA molecule itself,
leading to presentation of altered self-peptides. However,
identification of drug-associated antigenic peptides presented
by liver cells is more complicated due to the diverse subsets of
APCs in the liver. Several liver cell types located in the sinusoids
can serve as APCs to activate naiv̈e CD8+ T-cells. These include
hepatocytes, LSECs, KCs, and HSCs. Hepatocytes generally
express low levels of class I MHC molecules but can respond
with upregulation of heavy chain and β2m under immune-
stimulatory conditions, such as exposure to IFN-γ.65 Interest-
ingly, MHC-1 and ICAM-1 expression by hepatocytes was
found to be polarized to the basolateral surface facing the
sinusoids and is critical for CD8+ T-cell retention in the liver.66
However, the nature of antigenic peptides presented by liver
APCs remains undefined.
4. IMMUNOLOGICAL SIGNALS PROMOTE LIVER
INJURY
4.1. Cytokines. The release of pro-inflammatory cytokines
from damaged hepatocytes and innate immune cells can
influence DC activation and T-cell phenotype. In addition,
upon differentiation of naiv̈e T-cells to effector T-cells, different
cytokines are released by effector T-cells to carry out their
function. Pro-inflammatory cytokines such as TNF-α and IL-1β
can enhance inflammation and liver injury, whereas anti-
inflammatory cytokines including IL-10, IL-6, and IL-13 have
a protective function and prevent liver injury. TNF-α plays a
major role in the pathogenesis of DILI, and elevated plasma
levels were found to be associated with severity of DILI and
prognosis both in patients and animal models.67,68 Hepatotoxic
drugs such as APAP, troglitazone, and trovafloxacin significantly
increased LPS-induced IL-1β release in KCs, leading to an
imbalance between pro- and anti-inflammatory cytokines.69
IFN-γ has been shown to activate KCs and increase adhesion of
leukocytes through activation of the intracellular JAK signaling
and transcription activator STAT pathways, leading to
promotion of an inflammatory response and ultimately cell
death.70 In addition, the synergetic effects of two key cytokines,
IFN-γ and TNF-α, are known to cause the death of hepatocytes
and activation of the immune system.71 Distinct cytokine
expression and release profiles are strongly attributed to the
clinical features, prognosis, and progression of DILI.72 Global
metabolomics and proteomics approaches have now enabled
systemic evaluation of the cytokines associated with DILI,
providing new insight into the roles of these signals in immune-
mediated DILI.73
IL-10 is a key immuno-regulator to prevent the excessive
cytotoxic T-cell responses that are responsible for liver injury.
Substantially elevated IL-10 levels were observed in mice with
APAP overdose, and knockout of IL-10 in mice substantially
increases lethality of APAP.74 As a member of the IL-10 family,
IL-22 also has profound tissue-protective properties by
increasing tissue robustness and stress resistance, possibly
through activation of STA3 and the subsequent MAPK and Atk
pathways.75 Severe liver inflammation was observed in IL-22-
deficient mice treated with Concanavalin A (ConA, a known
cause of DILI). Blockage of IL-22 also results in increased liver
injury in an IL-22/CXCL10-dependent manner.76 IL-6 is also
well-known as a heptato-protective cytokine.77 The levels of IL-
6 are highly correlated with hepatocyte regeneration and severity
of liver injury. Serum elevated IL-6 levels were observed in
patients with liver diseases and mice treated with APAP.73,78 IL-
6 KO mice showed delayed regeneration after APAP, however,
enhanced regeneration and reduced APAP-induced liver injury
were observed by treatment with recombinant IL-6.74
It should be noted that the infection and inflammatory disease
can significantly influence the severity of DILI through effects on
the circulating cytokines. Several conditions of infection and
inflammation including influenza, HIV infection, and hepatitis B
and C have long been known to alter cytokine release. As
reviewed recently, increased pro-inflammatory cytokines such as
IFNγ, IL-6, IL-1β, and TNF-α can downregulate metabolizing
CYPs, drug transporters, and conjugative enzymes subsequently
affecting drug binding, transport, and bioavailability.79,80 P450
depression in the liver was at the highest upon treatment with
IL-1β, IL-6, and TNF-α.81 Likewise a Th2 cytokine response (IL
4, 5, and 13) resulted in downregulation of P450mRNAs inmice
with Schistosoma mansoni infection.82 Hepatic CYP down-
regulation is important in the elaboration or resolution of the
inflammatory response because it can prevent further oxidative
stress caused by drugs that are bioactivated by these enzymes.
Similarly, downregulation of UDP-glucuronosyltransferases,
sulfotransferases, GSH S-transferases, and transporters can
reduce the hepatic accumulation of cholesterol and its
derivatives, bile acids, and steroids, preventing further stress.80
It has been shown that the balance between the pro- and anti-
inflammatory cytokines determines the susceptibility and
severity of liver injury.83 However, the cytokine profiles in
patients with DILI have been shown to be extremely complex, in
particular, the complex interactions between individual
cytokines, which makes the interpretation of their roles in
DILI extremely difficult.84 Over a third of patients in a cytokine
release study of DILI patients did not fall into a unique defined
immune group, this is particularly due to numerous external
factors such as difference in causative drugs, underlying
conditions, gender differences, age, and ethnicity, demonstrating
the difficulty in determining cytokine profiles.72 In silico
modeling is required to evaluate the relationship between
cytokine networks and patient prognosis and severity of DILI.
4.2. Leukocytes Home to the Liver. Before T-cells can
exert a cytotoxic immune response in a particular location, they
must first be recruited or “homed” from the systemic circulation.
The inflammatory state is regulated by chemokines and their
subsequent receptors present on lymphocytes, which allow for
distinct immune populations to enter the liver.85 Chemokines
are characteristically small molecular weight proteins and can be
categorized into four different families (CC, CXC, CX3C, C)
based on the arrangement of the first two of four conserved
cysteine residues. These arrangements give rise to 50 chemokine
ligands and 20 cognate receptors, a number of which are
associated with DILI.86,87 However, before chemokines can be
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employed, immune cells must be slowed down in the circulation
to allow for sufficient interactions with chemokines presented by
endothelial cells; a process known as tethering and rolling.88 The
release of danger signals results in chemokine control and
management by hepatocytes, KCs, LSECs and HSCs. A number
of chemokines have been associated with the homing of T-cells
to the liver in inflammatory diseases including CCL25, CCL21
CCL3-5, CXCL9-11, CXCL16, and CCL4.89−92 However, the
role of chemokines in DILI is less well-defined. Monshi et al.
described the distinct chemokine receptor expression profile in
Figure 5. Hepatocytes are intrinsically tolerogenic. Through suicidal emperipolesis, hepatocytes can prevent proliferation of reactive T-cells.
Hepatocytes with an increased MHCII expression have also been shown to induce IL-10 secretion in naiv̈e CD4+ T-cells. KCs are known to
constitutively express the IL-10 receptor as well as excreting TGF-β and PGE2. KCs also exhibit anM2 anti-inflammatory phenotype upon stimulation
fromTLR4 and LPS, resulting in the down regulation ofMHCII, CD86, CD80, andCD40. In addition, the upregulation of Fas-L onKCs through IFN-
g induction has resulted in the elimination of activated T-cells. The upregulation of PD-L1 and release of IL-10, TGF-B, and PGE2 result in the
suppression of DC-mediated T-cells. LSECs have shown to actively suppress CD4+ T-cell effector function and cell contact-dependent suppression of
Th1 and Th17 responses but not proliferation. LSECs also have a number of bystander properties; one distinctive property is the expression of the
ligand for CD44 and LSECtin, inhibiting T-cell activation and proliferation. LSCEs can also prohibit inflammation by priming regulatory CD4+ T-
cells, shifting antigen-dependent immune responses to tolerance, especially under inflammatory conditions. The perisinusoidal space between LSECs
and hepatocytes is populated by HSCs. It has been shown that after inflammatory stress, HSCs release IL1Ra, IDO1, and IL-10, preventing
downstream pro-inflammatory signaling and microbial proliferation. HCSs show a marked increase in expression of PD-L1 which results in the
decreased responsiveness of T-cells associated with a high T-cell apoptotic rate. The production of IL-10 by HSCs has an inhibitory effect on DCs,
macrophages, and Th1 lymphocytes, andNKs promoting tolerance. DCs are key players in liver tolerance through inhibition of T-cell proliferation and
apoptosis of activated T-cells. Hepatic DCs promote tolerance though priming IL-10 producing T-regs, inducing the generation of CD4+CD25+
Tregs and through utilization of PD-L1 to induce and maintain T-cell unresponsiveness.
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flucloxacillin-specific T-cell clones isolated from DILI patients.
CCR2, CCR4, CCR9, and CXCR3 were found to be highly
expressed and resulted in migration of CD8+ drug clones in
vitro. The chemokine receptors CCR1, CCR3, CCR5, and
CXCR6 were expressed at low levels on a limited number of
clones.9
This distinct chemokine release profile has also been
demonstrated in KCs. Treatment with hepatotoxic compounds
results in the release of CCL3 and CXCL2 which have a key role
in filtration of various leukocytes and neutrophils into the liver.69
This is supported by the fact that there is a marked increase in
hepatic CCL3 expression after ConA treatment, resulting in the
recruitment of CD4+ T-cells to the liver, ultimately leading to
hepatic injury. Disruption of the CCL3 gene significantly
reduced concanavalin-induced hepatitis.93 A study assessing the
profiles of serum cytokines and chemokines in acute DILI found
that the chemokines CCL3 and RANTES (CCL5) were
marginally associated with mortality within 6 months of DILI
onset based on univariate analyses.72 This study highlights the
role of chemokine receptors in the homing of immune cells to
the liver, the promotion of an inflammatory environment, and
eventually toxicity. CCL5 has also been found to be in higher
abundance in DILI patients compared to those in the ALF
group.73 Furthermore, the treatment of DCs with SMX-NO
treated hepatocyte conditioned medium found an increase in
CCR1 and CD40 expression.24 The increase of CCR1, possibly
in response to an increased expression of CCL16 released by
SMX-NO stressed hepatocytes, is vital for the migration of DCs
to the liver.
4.3. The Interaction of Immune Cells with Hepato-
cytes. How circulating drug-specific T-cells interact with
hepatocytes after they have extravagated into the liver is less
well understood. The liver sinusoids, lined by LSECs, play an
important role in cellular communications. LESCs, which lack
tight junctions as well as a basal membrane, allow direct
interaction of circulating and liver residential leukocytes with
underlying hepatocytes.66,94,95 Dynamic imaging revealed that
CD8+ T-cells crawl along liver sinusoids independent of blood
direction, surveying hepatocytes for antigens through sinusoidal
fenestrae. Following antigen recognition on hepatocytes, CD8+
T-cells slowed down and eventually arrested. In general,
hepatocyte-activated CD8+ T-cells developed poor cytotoxic
function and subsequently died by Bim-dependent apoptosis.96
However, antigen-specific CD8+ T-cells, particularly those
activated by high affinity antigens, can kill hepatocytes through
perforin and Fas ligand (FasL)-mediated mechanisms.97
Although hepatocytes express high levels of Fas and are highly
susceptible to apoptosis, hepatocyte damage by infiltrating T-
cells is not exclusively caused by the FasL-mediated killing
pathway. Additional effector molecules such as TNF-α, IFN-γ,
and granzyme Bmay also be involved due to the heterogeneity of
T-cells. Since drug-specific T-cells can be activated by multiple
mechanisms, how these T-cells damage hepatocytes remains
largely unknown. However, recent studies demonstrated that
flucloxacillin-specific CD8+ T-cells can kill hepatocytes through
the release of cytolytic mediators such as IFN-γ and granzyme
B.8,9 Interestingly, MHC molecules also play an important role
in the interactions between T-cells and hepatocytes. Confocal
immunofluorescence and flow cytometric analyses demonstra-
ted that only MHC-matched CD8+ T-cells isolated from the
liver of HBV replication-competent transgenic mice eventually
extravasate into the liver parenchyma.98 In addition, fluclox-
acillin-specific T-cells can kill hepatocytes in a HLA-B*57:01
restricted manner.8
5. THE ROLES OF IMMUNE TOLERANCE AND
ADAPTATION IN DILI
The liver is routinely exposed to foreign antigens that are
ingested and metabolized or excreted via the biliary system.
Therefore, the liver has been privileged with a large capacity for
peripheral immune tolerance. Immune tolerance is a critical
adaptation to protect hepatocytes from suffering a constant state
of inflammation. Experimental studies have been able to
establish and maintain allogeneic liver grafts in animal models
without the need for immunosuppression.99 Likewise the ability
to transplant the liver without HLA matching and rejection has
led to the phenomena known as spontaneous operational
tolerance.100,101 The liver maintains this tolerance through a
number or processes (Figure 5): the control of antigen
activation and presentation, clonal deletion (apoptosis of
antigen-specific T-cells), and immune deviation (switching
from Th2 and Th1).102
5.1. Hepatocytes Are Intrinsically Tolerogenic. Hep-
atocytes have the capability of inducing activation and
proliferation of naiv̈e CD8+ T-cells. However, without the
presence of co-stimulatory molecules, these hepatocyte-
activated CD8+ T-cells demonstrate poor effector function
and early BIM-dependent apoptosis, representing an acquired
tolerant phenotype.96 Interestingly, the thresholds of antigen
presentation by hepatocytes appear to be vital in balancing a
tolerogenic versus an effector immune response: It has been
shown that the low levels of hepatocellular antigens lead to an
effector CD8+ T-cell response, whereas the abundance of
antigens causes CD8+ T-cell exhaustion and silence.103 Another
mechanism by which the liver promotes a tolerogenic
environment is through peripheral deletion of self-reactive T-
cells.104 Hepatocytes also determine the nonapoptotic destruc-
tion of activated CD8+ T-cells through lysosomal proteolytic
enzyme degradation; a process known as suicidal emperipolesis
(SE). This process is rapid and prevents proliferation and
expansion of reactive T-cells. Inhibition of SE is associated with
preclusion of tolerance and promotes liver damage.105
Hepatocytes with an increased MHC II expression have been
shown to induce IL-10 secretion in naiv̈e CD4+T-cells in vitro in
a Notch receptor-dependent manner, playing a central role in
tolerance.106 It is well understood that the liver competes with
lymphoid tissue to determine T-cell activation and fate, with the
former promoting tolerance.107 All of these mechanisms denote
that the liver, under steady-state conditions, prefers and
promotes a tolerogenic environment.
5.2. Tolerance Promoted by APCs in the Liver. The
tolerogenic environment in the liver is also partly attributed to
the effects of KCs, LSECs, or HSCs as APCs and the distinctive
liver-resident DCs.108,109 Liver APCs can promote tolerance
through multiple pathways, including secretion of a range of
anti-inflammatory cytokines, suppression of effector CD4+ and
CD8+ T-cells, and induction of Tregs.
KCs are liver resident macrophages that play a critical role in
modulating tolerance in the liver. KCs are known to secret IL-10
and a range of anti-inflammatory and immunosuppressive
factors such as nitric oxide, TGFβ or arachidonic acid metabolite
prostaglandin E2.110 One remarkable feature of KCs is their
ability to exhibit an anti-inflammatory M2-like macrophage
polarization state upon signals from LPS and TLR4, protecting
the liver from injury by inhibiting pro-inflammatory cytokine
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production and attraction of Tregs to the liver.111 It is thought
that this shift from M1 to M2 phenotype is a result of the
interaction between mesenchymal cells and KCs. The
expression of MHC II, CD86, CD80, and CD40 was
significantly decreased in the presence of mesenchymal cells.
In addition to the cytokine release and APC properties, KCs can
modulate tolerance in the liver through either immune
inhibition by increased expression of PD-L1 or elimination of
activated T-cells by upregulation of Fas-L.112
LSECs represent a unique population of scavenger APCs
which facilitate the passage of molecules from the sinusoidal
lumen into the space of Disse through their fenestrae or sieve
plates and a lack of a continuous basement membrane. Through
increased expression of PD-L1, LSECs can induce antigen-
specific tolerance in CD8+ T-cells through cross-presentation of
antigens from damaged hepatocytes. LSEC-primed CD8+ T-
cells acquire a memory-like phenotype and express the lymphoid
adhesion CD62L. Unlike their CD4+ counterparts, the CD8+
cells do not migrate to the gut but return to the secondary
lymphoid organs, where they can reactivated by DCs to support
anti-infection immunity.113 In addition, LSECs have shown to
actively suppress CD4+ T-cells effector function and cell
contact-dependent suppression of Th1 and Th17 responses,
but not proliferation.114 Moreover, compared to other liver cell
types, LSECs have shown to be the most efficient in inducing
fork-head-winged helix transcription factor (Foxp3+) Tregs in
the liver. Treg induction by LESCs occurred in a TGFβ-
dependent and antigen-specific manner.115
HSCs, located at the perisinusoidal space between LSECs and
hepatocytes, also play a critical role in immune regulation and
suppression within the liver. It is well understood that HSCs
release anti-inflammatory mediators which prevent activation
and progression to an inflammatory state. After inflammatory
stress, HSCs release IL1Ra, IDO1, and IL-10, promoting
tolerance and preventing the immune system from mounting a
response.116 In addition, activated HCSs show a marked
increase in expression of PD-L1, which results in the decreased
responsiveness of T-cells associated with a high T-cell apoptotic
rate.117 Moreover, in the presence of DCs, HSCs inhibit
activation of CD8+ T-cells via a CD54-dependent mechanism
and promote differentiation of naiv̈e CD4+ to Tregs.118119
DCs also play a crucial role in promoting tolerance within the
liver. The reprogramming of CD117+ hematopoietic progenitor
cells to differentiate into tolerogenic DCs which suppress T-cell
proliferation and induce apoptosis of activated T-cells is
promoted by the liver microenvironment.120 Liver DCs promote
tolerance though priming IL-10 producing T-regs, inducing the
generation of CD4+CD25+ Tregs and through utilization of
PD-L1 to induce and maintain T-cell unresponsiveness.121 In
addition, pDCs show a high expresson of NOD that down-
regulates immune response through increasing PD-L1 ex-
pression, dampen TLR signaling, and inhibition of pro-
inflammatory cytokine secretion (IL-6, IL12p70, TNF-a, and
IFN-y).122 The fine-tuned interaction between hepatic Treg
population and DCs is responsible for the maintenance of a
tolerogenic environment within the liver.
5.3. Dysregulation and Disruption of Tolerance
Pathways. Understanding the mechanisms by which the fine-
tuned tolerance pathways are disrupted in a range of other
disease states such as infection and inflammation may provide
insight into the mechanisms behind the progression of DILI.
Over a quarter of most common DILI drugs are indicated as
antimicrobials or antibiotics, suggesting patients have recently
suffered a microbial infection.123 One possible concept is that
certain bacterial infections or disease states are associated with
unique changes in the gut microbiota profile, which may be
linked to diffusion of normal tolerance pathways. As the liver
interacts with the gut through the hepatic portal and bile
secretion systems, gut microbiota as well as bacterial endotoxins
(such as LPS) and their regulation pathways could be associated
with liver disease. This theory raises the possibility that the
concurrent infection and inflammation may render an individual
more susceptible to DILI. However, the translocation of
endotoxins or the presence of modest inflammation cannot be
labeled as the sole trigger disrupting tolerance but a contributing
factor. In addition, disruption of liver tolerance through immune
checkpoint inhibitors (ICIs) treatment that commonly block
B7/CTLA-4 and PD1/PD-L1 pathways can promote the
activation and proliferation of effector T-cells, resulting in
immune-mediated liver injury. Indeed, the incidence of
immune-related acute hepatitis of all grades is estimated to
affect 4−9% of patients with monotherapy, and 18% of patients
treated with the combination therapy. Treatment of ICIs has led
to massive infiltration of lymphocytes, largely CD8+ T-cells, in
portal tracts and lobules, resulting in inflammatory liver
injury.124 In an animal model with an impaired immune
tolerance, Uetrecht et al. showed that co-treatment of C57BL/6
mice with amodiaquine and anit-CTLA4 resulted in a greater
injury than treatment with amodiaquine alone.125 Together the
intrinsic toxicity of the drug, individual differences and external
factors, cell population changes as well as pre-existing
inflammation may contribute to impair the liver tolerance,
resulting in increased liver injury.
6. CONCLUSION
Advanced bioanalysis has enabled characterization of both stable
and potentially reactive metabolites that may be involved in
DILI. In particular, recent investigations using immunopepti-
domics have enabled the identification of drug associated
antigens that may be involved in the activation of T-cells.
However, the hepatic protein targets and the exact location of
neoantigens formed in the liver remain to be investigated. It is
worth noting that the formation of neoantigens may be
important for initiating an immune response, but this process
alone will not always result in liver injury. Indeed, circulating
drug-modified proteins have been detected in patients without
DILI.43,44 Therefore, the critical question remains, what
determines switching from tolerance to immunity?
Although considerable progress has been made in under-
standing the molecular and cellular mechanisms underlying
DILI, the lack of in vitro and animal models, and definitive
prognostic biomarkers, makes the prediction and prevention of
immune-mediated DILI extremely challenging. Recent advances
in developing a more physiological in vitro model, such as liver-
derived organoids,126,127 has made the future prediction of DILI
more promising. Specifically, the co-culture of immune cells
with target cells, such as hepatocytes, has allowed us to
investigate the complex cellular mechanisms involved in killing
target cells (Unpublished data). Importantly, co-culturing
immune cells with hepatocytes expressing specific HLA risk
alleles will provide a valuable system for addressing patient-
specific factors contributing to DILI. As it is challenging to
achieve the same balance between tolerance and immunity
occurring in the liver, developing in vitromodels for investigating
the mechanisms of immune-mediated DILI has been problem-
atic. However, recent attempts using HLA transgenic animal
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models with impaired immune tolerance have shown some
promising results. Transgenic mice positive for HLA-B*57:01
showed induced toxicity to abacavir, in contrast to those carrying
HLA-B*57:03.While abacavir hypersensitivity does not result in
liver injury, these models will be particularly valuable for the
preclinical screening of the immunogenicity of new drug
candidates if they can be applied to general DILI
drugs.125,128,129 Due to the complexity of both innate and
adaptive immunity involved in DILI, physiologically relevant in
vitro models incorporating both immune and liver cells are in
great need. In particular, co-culturing hepatic cells derived from
human pluripotent stem cells with HLA matched drug-specific
immune cells will allow the monitoring of immune-mediated
toxicity. Moreover, future study on the patient related risk
factors such as disease states and regulatory pathways that
determine susceptibility to DILI will certainly provide an
opportunity to develop better predictive test systems for the
prediction and prevention of DILI.
■ AUTHOR INFORMATION
Corresponding Author




‡These authors contributed equally to this work.
Funding
This work was supported by the Medical Research Council
Centre for Drug Safety Science (grant number MR/L006758/
1). S.A. is a MRC DiMeN Ph.D. student.
Notes
The authors declare no competing financial interest.
Biographies
Dr. Xiaoli Meng received her Ph.D. in medicinal chemistry from the
University of Liverpool, with a focus on the synthesis of reactive drug
metabolites. She is currently working in theMRCCentre of Drug Safety
Science (CDSS) at the University of Liverpool as a research fellow. Her
research focuses on understanding the mechanisms of immune-
mediated adverse drug reactions by defining the chemistry of the
molecules that drive the reactions. She currently leads the
immunopeptidomics group at CDSS that focuses on the identification
of naturally processed and presented antigenic peptides that could
initiate an immune response.
James C. Waddington obtained a Master of Biological Sciences degree
from the University of Liverpool in 2015, with honors in microbiology.
Previous research focuses included the implementation of novel
techniques to analyze microbial metagenomics signatures in order to
identify disease biomarkers, cellular responses to HIV viral infection,
and toxin gene regulation in bacterial viruses. In 2015, James joined the
MRCCentre for Drug Safety Science at the University of Liverpool as a
Ph.D. student in pharmacology. Current research focuses on the
characterization of naturally processed MHC peptides that act as T-cell
antigens in patients with drug hypersensitivity.
Serat-E Ali joined the MRC Centre for Drug Safety Science at the
University of Liverpool in 2017 as part of theMRCDiscoveryMedicine
North DTP. His current project focuses on developing in vitro cell-
based systems to investigate the killing of target tissue by drug-specific
T-cells. Prior to joining the centre, Serat-E obtained aMasters degree in
toxicology and pharmacology with honors in biomedical science from
the University of Bradford. His previous research focuses include
assessing penetration and binding of novel chemotherapeutic drugs in
multicellular spheroids using HPLC and mass spectrometry.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
K
Professor Kevin Park is Professor of Pharmacology, Head of the
Institute of Translational Medicine at the University of Liverpool, and
Director of the UKRMP Safety Hub. He was the founding Director of
the MRC Centre for Drug Safety Science. Professor Park is a Fellow of
the Royal College of Physicians and a Fellow of the Academy ofMedical
Sciences. His work bridges “molecule-to-man” and back again for
prediction of adverse drug reactions based on the chemistry of the drug
and the identification of susceptible individuals. More recently his work
has expanded to understand the safety and efficacy of regenerative
medicines.
■ ABBREVIATIONS
AHS, abacavir hypersensitivity syndrome; APAP, acetamino-
phen; ALF, acute liver failure; ADA, antidrug antibody; TNF,
antitumor necrosis factor; APCs, antigen presenting cells;
ConA, Concanavalin A; DAMPs, damage-associated molecular
patterns; DCs, dendritic cells; Foxp3, fork-head-winged helix
transcription factor; HSP, heat shock protein; HSCs, hepatic
stellate cells; GSH, glutathione; HMGB1, high mobility group
box 1; HLA, human leukocyte antigen; HSA, human serum
albumin; iDILI, idiosyncratic drug-induced liver injury; KCs,
Kupffer cells; LSECs, liver sinusoidal endothelial cells; NAPQI,
N-acetyl-p-benzoquinone imine; NK, natural killer; NVP,
nevaripine; NSAIDs, nonsteroidal anti-inflammatory drugs;
PD-1, programmed cell death protein 1; PD-L1, PD-ligand1;
RMs, reactive metabolites; SE, suicidal emperipolesis; SMX-
NO, sulfamethoxazole nitroso; TCRs, T-cell receptors; TPs,
therapeutic proteins; TLRs, toll-like receptors; TNF, tumor
necrosis factor
■ REFERENCES
(1) Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C.,
Guilleminet, C., Lenoir, C., Lemoine, A., and Hillon, P. (2002)
Incidence of drug-induced hepatic injuries: a French population-based
study. Hepatology 36, 451−455.
(2) Danan, G., and Benichou, C. (1993) Causality assessment of
adverse reactions to drugs–I. A novel method based on the conclusions
of international consensus meetings: application to drug-induced liver
injuries. J. Clin Epidemiol 46, 1323−1330.
(3) Tailor, A., Faulkner, L., Naisbitt, D. J., and Park, B. K. (2015) The
chemical, genetic and immunological basis of idiosyncratic drug-
induced liver injury. Hum. Exp. Toxicol. 34, 1310−1317.
(4) Michalopoulos, G. K. (2017) Hepatostat: Liver regeneration and
normal liver tissue maintenance. Hepatology 65, 1384−1392.
(5) Doherty, D. G. (2016) Immunity, tolerance and autoimmunity in
the liver: A comprehensive review. J. Autoimmun. 66, 60−75.
(6) Jenne, C. N., and Kubes, P. (2013) Immune surveillance by the
liver. Nat. Immunol. 14, 996−1006.
(7) Metushi, I. G., Sanders, C., Lee, W. M., and Uetrecht, J. (2014)
Detection of anti-isoniazid and anti-cytochrome P450 antibodies in
patients with isoniazid-induced liver failure.Hepatology 59, 1084−1093.
(8) Wuillemin, N., Terracciano, L., Beltraminelli, H., Schlapbach, C.,
Fontana, S., Krahenbuhl, S., Pichler, W. J., and Yerly, D. (2014) T cells
infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated
floxacillin-induced liver injury. Am. J. Pathol. 184, 1677−1682.
(9) Monshi, M. M., Faulkner, L., Gibson, A., Jenkins, R. E., Farrell, J.,
Earnshaw, C. J., Alfirevic, A., Cederbrant, K., Daly, A. K., French, N.,
Pirmohamed, M., Park, B. K., and Naisbitt, D. J. (2013) Human
leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific
T cells provides the immunological basis for flucloxacillin-induced liver
injury. Hepatology 57, 727−739.
(10) Kim, S. H., Saide, K., Farrell, J., Faulkner, L., Tailor, A., Ogese,M.,
Daly, A. K., Pirmohamed, M., Park, B. K., and Naisbitt, D. J. (2015)
Characterization of amoxicillin- and clavulanic acid-specific T cells in
patients with amoxicillin-clavulanate-induced liver injury. Hepatology
62, 887−899.
(11) Usui, T., Meng, X., Saide, K., Farrell, J., Thomson, P., Whitaker,
P., Watson, J., French, N. S., Kevin Park, B., and Naisbitt, D. J. (2017)
From the Cover: Characterization of Isoniazid-Specific T-Cell Clones
in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury.
Toxicol. Sci. 155, 420−431.
(12) Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P.,
Andrade, R. J., Day, C. P., Ruiz-Cabello, F., Donaldson, P. T., Stephens,
C., Pirmohamed, M., Romero-Gomez, M., Navarro, J. M., Fontana, R.
J., Miller, M., Groome, M., Bondon-Guitton, E., Conforti, A., Stricker,
B. H.C., Carvajal, A., Ibanez, L., Yue, Q.-Y., Eichelbaum, M., Floratos,
A., Pe'er, I., Daly, M. J., Goldstein, D. B., Dillon, J. F., Nelson, M. R.,
Watkins, P. B., and Daly, A. K. (2011) Susceptibility to amoxicillin-
clavulanate-induced liver injury is influenced by multiple HLA class I
and II alleles. Gastroenterology 141, 338−347.
(13) Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya,
T., Mori, K., Shimizu, S., Masumoto, H., and Okutani, Y. (2008)
Ticlopidine-induced hepatotoxicity is associated with specific human
leukocyte antigen genomic subtypes in Japanese patients: a preliminary
case-control study. Pharmacogenomics J. 8, 29−33.
(14) Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J.,
Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E.,
Gibson, N. J., Armstrong, M., Lagerstrom-Fermer, M. E., Dellsen, A.,
Brown, E. M., Thornton, M., Dukes, C., Jenkins, S. C., Firth, M. A.,
Harrod, G. O., Pinel, T. H., Billing-Clason, S. M., Cardon, L. R., and
March, R. E. (2008) Genome-wide pharmacogenetic investigation of a
hepatic adverse event without clinical signs of immunopathology
suggests an underlying immune pathogenesis. Pharmacogenomics J. 8,
186−195.
(15) Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe’er, I.,
Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R.,
Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, H. J.,
Pirmohamed, M., Aithal, G. P., and Day, C. P. (2009) HLA-B*5701
genotype is a major determinant of drug-induced liver injury due to
flucloxacillin. Nat. Genet. 41, 816−819.
(16) Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein,
L., Wright, T. M., Meyer, J., and Paulding, C. A. (2010) A genome-wide
study identifies HLA alleles associated with lumiracoxib-related liver
injury. Nat. Genet. 42, 711−714.
(17) Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J.,
King, K. S., Whittaker, J. C., Mooser, V. E., Preston, A. J., Stein, S. H.,
and Cardon, L. R. (2011) HLA-DQA1*02:01 is a major risk factor for
lapatinib-induced hepatotoxicity in women with advanced breast
cancer. J. Clin. Oncol. 29, 667−673.
(18) Schulze, R. J., Schott, M. B., Casey, C. A., Tuma, P. L., and
McNiven, M. A. (2019) The cell biology of the hepatocyte: A
membrane trafficking machine. J. Cell Biol. 218, 2096.
(19) Trefts, E., Gannon, M., and Wasserman, D. H. (2017) The liver.
Curr. Biol. 27, R1147−R1151.
(20) Kouwaki, T., Okamoto, M., Tsukamoto, H., Fukushima, Y., and
Oshiumi, H. (2017) Extracellular Vesicles Deliver Host and Virus RNA
and Regulate Innate Immune Response. Int. J. Mol. Sci. 18, 666.
(21) Holman, N. S., Church, R. J., Nautiyal, M., Rose, K. A., Thacker,
S. E., Otieno, M. A., Wolf, K. K., LeCluyse, E., Watkins, P. B., and
Mosedale, M. (2019) Hepatocyte-Derived Exosomes Promote Liver
Immune Tolerance: Possible Implications for Idiosyncratic Drug-
Induced Liver Injury. Toxicol. Sci. 170, 499.
(22) Krenkel, O., Mossanen, J. C., and Tacke, F. (2014) Immune
mechanisms in acetaminophen-induced acute liver failure. Hepatobili-
ary Surg. Nutr. 3, 331−343.
(23) Tamura, Y., Torigoe, T., Kukita, K., Saito, K., Okuya, K., Kutomi,
G., Hirata, K., and Sato, N. (2012) Heat-shock proteins as endogenous
ligands building a bridge between innate and adaptive immunity.
Immunotherapy 4, 841−852.
(24)Ogese,M. O., Faulkner, L., Jenkins, R. E., French, N. S., Copple, I.
M., Antoine, D. J., Elmasry, M., Malik, H., Goldring, C. E., Park, B. K.,
Betts, C. J., and Naisbitt, D. J. (2017) Characterization of Drug-Specific
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
L
Signaling Between Primary Human Hepatocytes and Immune Cells.
Toxicol. Sci. 158, 76−89.
(25) Oda, S., Shirai, Y., Akai, S., Nakajima, A., Tsuneyama, K., and
Yokoi, T. (2017) Toxicological role of an acyl glucuronidemetabolite in
diclofenac-induced acute liver injury in mice. J. Appl. Toxicol. 37, 545−
553.
(26) Masson, M. J., Peterson, R. A., Chung, C. J., Graf, M. L.,
Carpenter, L. D., Ambroso, J. L., Krull, D. L., Sciarrotta, J., and Pohl, L.
R. (2007) Lymphocyte loss and immunosuppression following
acetaminophen-induced hepatotoxicity in mice as a potential
mechanism of tolerance. Chem. Res. Toxicol. 20, 20−26.
(27) Neuberger, J., and Williams, R. (1989) Immune mechanisms in
tienilic acid associated hepatotoxicity. Gut 30, 515−519.
(28) Jo, M., Kim, T. H., Seol, D. W., Esplen, J. E., Dorko, K., Billiar, T.
R., and Strom, S. C. (2000) Apoptosis induced in normal human
hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.
Nat. Med. 6, 564−567.
(29) Zuch de Zafra, C. L., Ashkenazi, A., Darbonne, W. C., Cheu, M.,
Totpal, K., Ortega, S., Flores, H., Walker, M. D., Kabakoff, B., Lum, B.
L., Mounho-Zamora, B. J., Marsters, S. A., and Dybdal, N. O. (2016)
Antitherapeutic antibody-mediated hepatotoxicity of recombinant
human Apo2L/TRAIL in the cynomolgus monkey. Cell Death Dis. 7,
e2338.
(30) Baker, M. P., Reynolds, H. M., Lumicisi, B., and Bryson, C. J.
(2010) Immunogenicity of protein therapeutics: The key causes,
consequences and challenges. Self Nonself 1, 314−322.
(31) Metushi, I. G., Zhu, X., Chen, X., Gardam, M. A., and Uetrecht, J.
(2014) Mild isoniazid-induced liver injury in humans is associated with
an increase in Th17 cells and T cells producing IL-10. Chem. Res.
Toxicol. 27, 683−689.
(32) Kaliyaperumal, K., Grove, J. I., Delahay, R. M., Griffiths, W. J. H.,
Duckworth, A., and Aithal, G. P. (2018) Pharmacogenomics of drug-
induced liver injury (DILI): Molecular biology to clinical applications.
J. Hepatol. 69, 948−957.
(33) Pirmohamed, M., Ostrov, D. A., and Park, B. K. (2015) New
genetic findings lead the way to a better understanding of fundamental
mechanisms of drug hypersensitivity. J. Allergy Clin. Immunol. 136,
236−244.
(34) Illing, P. T., Purcell, A. W., and McCluskey, J. (2017) The role of
HLA genes in pharmacogenomics: unravelling HLA associated adverse
drug reactions. Immunogenetics 69, 617−630.
(35) Alfirevic, A., and Pirmohamed, M. (2012) Predictive genetic
testing for drug-induced liver injury: considerations of clinical utility.
Clin. Pharmacol. Ther. 92, 376−380.
(36) Xu, C. F., Johnson, T., Wang, X., Carpenter, C., Graves, A. P.,
Warren, L., Xue, Z., King, K. S., Fraser, D. J., Stinnett, S., Briley, L. P.,
Mitrica, I., Spraggs, C. F., Nelson, M. R., Tada, H., du Bois, A., Powles,
T., Kaplowitz, N., and Pandite, L. N. (2016) HLA-B*57:01 Confers
Susceptibility to Pazopanib-Associated Liver Injury in Patients with
Cancer. Clin. Cancer Res. 22, 1371−1377.
(37) Keane, N. M., Pavlos, R. K., McKinnon, E., Lucas, A., Rive, C.,
Blyth, C. C., Dunn, D., Lucas, M., Mallal, S., and Phillips, E. (2014)
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are
implicated in the pathogenesis of nevirapine hypersensitivity. AIDS 28,
1891−1901.
(38) Huang, K., Huang, L., and van Breemen, R. B. (2015) Detection
of reactive metabolites using isotope-labeled glutathione trapping and
simultaneous neutral loss and precursor ion scanning with ultra-high-
pressure liquid chromatography triple quadruple mass spectrometry.
Anal. Chem. 87, 3646−3654.
(39) Wang, Z., Fang, Y., Rock, D., and Ma, J. (2018) Rapid screening
and characterization of glutathione-trapped reactive metabolites using a
polarity switch-based approach on a high-resolution quadrupole
orbitrap mass spectrometer. Anal. Bioanal. Chem. 410, 1595−1606.
(40) Yip, V. L. M., Meng, X., Maggs, J. L., Jenkins, R. E., Marlot, P. T.,
Marson, A. G., Park, B. K., and Pirmohamed, M. (2017) Mass
Spectrometric Characterization of Circulating Covalent Protein
Adducts Derived from Epoxide Metabolites of Carbamazepine in
Patients. Chem. Res. Toxicol. 30, 1419−1435.
(41) Laine, J. E., Hakkinen, M. R., Auriola, S., Juvonen, R. O., and
Pasanen, M. (2015) Comparison of trapping profiles between d-
peptides and glutathione in the identification of reactive metabolites.
Toxicol Rep 2, 1024−1032.
(42) Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D.,
Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S.,
Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A.,
Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie,
T. A. (2011)Managing the challenge of chemically reactive metabolites
in drug development. Nat. Rev. Drug Discovery 10, 292−306.
(43) Meng, X., Earnshaw, C. J., Tailor, A., Jenkins, R. E., Waddington,
J. C., Whitaker, P., French, N. S., Naisbitt, D. J., and Park, B. K. (2016)
Amoxicillin and Clavulanate Form Chemically and Immunologically
Distinct Multiple Haptenic Structures in Patients. Chem. Res. Toxicol.
29, 1762−1772.
(44) Jenkins, R. E., Meng, X., Elliott, V. L., Kitteringham, N. R.,
Pirmohamed, M., and Park, B. K. (2009) Characterisation of
flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in
vitro and in vivo. Proteomics: Clin. Appl. 3, 720−729.
(45) Meng, X., Jenkins, R. E., Berry, N. G., Maggs, J. L., Farrell, J.,
Lane, C. S., Stachulski, A. V., French, N. S., Naisbitt, D. J., Pirmohamed,
M., and Park, B. K. (2011) Direct evidence for the formation of
diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and
benzylpenicillenic acid in patients. J. Pharmacol. Exp. Ther. 338, 841−
849.
(46) Singh, J., Petter, R. C., Baillie, T. A., and Whitty, A. (2011) The
resurgence of covalent drugs. Nat. Rev. Drug Discovery 10, 307−317.
(47) Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein,
C., Kraemer, O., Himmelsbach, F., Haaksma, E., and Adolf, G. R.
(2012) Target binding properties and cellular activity of afatinib
(BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp.
Ther. 343, 342−350.
(48) Tafesh, Z. H., Coleman, M., Fulmer, C., and Nagler, J. (2019)
Severe Hepatotoxicity due to Ibrutinib with a Review of Published
Cases. Case Rep. Gastroenterol 13, 357−363.
(49) Ding, P. N., Lord, S. J., Gebski, V., Links,M., Bray, V., Gralla, R. J.,
Yang, J. C., and Lee, C. K. (2017) Risk of Treatment-Related Toxicities
from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical
Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated
Non-Small Cell Lung Cancer. J. Thorac. Oncol. 12, 633−643.
(50) Wang, J., Li-Chan, X. X., Atherton, J., Deng, L., Espina, R., Yu, L.,
Horwatt, P., Ross, S., Lockhead, S., Ahmad, S., Chandrasekaran, A.,
Oganesian, A., Scatina, J., Mutlib, A., and Talaat, R. (2010)
Characterization of HKI-272 covalent binding to human serum
albumin. Drug Metab. Dispos. 38, 1083−1093.
(51) Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A.,
Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T. M., Chang, B. Y., Larkin,
K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L.,
Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K.,
Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A.,
Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., and Byrd, J.
C. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving
a Th1-selective pressure in T lymphocytes. Blood 122, 2539−2549.
(52) Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S.,
Dillon, M. B., Bachovchin, D. A., Mowen, K., Baker, D., and Cravatt, B.
F. (2010) Quantitative reactivity profiling predicts functional cysteines
in proteomes. Nature 468, 790−795.
(53) Niessen, S., Dix, M. M., Barbas, S., Potter, Z. E., Lu, S., Brodsky,
O., Planken, S., Behenna, D., Almaden, C., Gajiwala, K. S., Ryan, K.,
Ferre, R., Lazear, M. R., Hayward, M. M., Kath, J. C., and Cravatt, B. F.
(2017) Proteome-wide Map of Targets of T790M-EGFR-Directed
Covalent Inhibitors. Cell Chem. Biol. 24, 1388−1400.
(54) Browne, C. M., Jiang, B., Ficarro, S. B., Doctor, Z. M., Johnson, J.
L., Card, J. D., Sivakumaren, S. C., Alexander, W. M., Yaron, T. M.,
Murphy, C. J., Kwiatkowski, N. P., Zhang, T., Cantley, L. C., Gray, N. S.,
and Marto, J. A. (2019) A Chemoproteomic Strategy for Direct and
Proteome-Wide Covalent Inhibitor Target-Site Identification. J. Am.
Chem. Soc. 141, 191−203.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
M
(55) Heard, K., Green, J. L., Anderson, V., Bucher-Bartelson, B., and
Dart, R. C. (2016) Paracetamol (acetaminophen) protein adduct
concentrations during therapeutic dosing. Br. J. Clin. Pharmacol. 81,
562−568.
(56) Heard, K. J., Green, J. L., James, L. P., Judge, B. S., Zolot, L.,
Rhyee, S., and Dart, R. C. (2011) Acetaminophen-cysteine adducts
during therapeutic dosing and following overdose. BMC Gastroenterol.
11, 20.
(57) Davern, T. J., 2nd, James, L. P., Hinson, J. A., Polson, J., Larson,
A. M., Fontana, R. J., Lalani, E., Munoz, S., Shakil, A. O., and Lee, W.M.
(2006) Measurement of serum acetaminophen-protein adducts in
patients with acute liver failure. Gastroenterology 130, 687−694.
(58) Sharma, A. M., Li, Y., Novalen, M., Hayes, M. A., and Uetrecht, J.
(2012) Bioactivation of nevirapine to a reactive quinone methide:
implications for liver injury. Chem. Res. Toxicol. 25, 1708−1719.
(59) Hammond, T. G., Meng, X., Jenkins, R. E., Maggs, J. L.,
Castelazo, A. S., Regan, S. L., Bennett, S. N., Earnshaw, C. J., Aithal, G.
P., Pande, I., Kenna, J. G., Stachulski, A. V., Park, B. K., andWilliams, D.
P. (2014) Mass spectrometric characterization of circulating covalent
protein adducts derived from a drug acyl glucuronide metabolite:
multiple albumin adductions in diclofenac patients. J. Pharmacol. Exp.
Ther. 350, 387−402.
(60) Dong, J. Q., Liu, J., and Smith, P. C. (2005) Role of benoxaprofen
and flunoxaprofen acyl glucuronides in covalent binding to rat plasma
and liver proteins in vivo. Biochem. Pharmacol. 70, 937−948.
(61) Skonberg, C., Olsen, J., Madsen, K. G., Hansen, S. H., and Grillo,
M. P. (2008) Metabolic activation of carboxylic acids. Expert Opin.
Drug Metab. Toxicol. 4, 425−438.
(62) Norcross, M. A., Luo, S., Lu, L., Boyne, M. T., Gomarteli, M.,
Rennels, A. D.,Woodcock, J., Margulies, D. H.,McMurtrey, C., Vernon,
S., Hildebrand, W. H., and Buchli, R. (2012) Abacavir induces loading
of novel self-peptides into HLA-B*57:01: an autoimmune model for
HLA-associated drug hypersensitivity. AIDS 26, F21−29.
(63) Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z.,
Bharadwaj, M., Miles, J. J., Kjer-Nielsen, L., Gras, S., Williamson, N. A.,
Burrows, S. R., Purcell, A. W., Rossjohn, J., and McCluskey, J. (2012)
Immune self-reactivity triggered by drug-modified HLA-peptide
repertoire. Nature 486, 554−558.
(64) Ostrov, D. A., Grant, B. J., Pompeu, Y. A., Sidney, J., Harndahl,
M., Southwood, S., Oseroff, C., Lu, S., Jakoncic, J., de Oliveira, C. A.,
Yang, L., Mei, H., Shi, L., Shabanowitz, J., English, A. M., Wriston, A.,
Lucas, A., Phillips, E., Mallal, S., Grey, H. M., Sette, A., Hunt, D. F.,
Buus, S., and Peters, B. (2012) Drug hypersensitivity caused by
alteration of the MHC-presented self-peptide repertoire. Proc. Natl.
Acad. Sci. U. S. A. 109, 9959−9964.
(65) Chen, M., Tabaczewski, P., Truscott, S. M., Van Kaer, L., and
Stroynowski, I. (2005) Hepatocytes express abundant surface class I
MHC and efficiently use transporter associated with antigen
processing, tapasin, and low molecular weight polypeptide proteasome
subunit components of antigen processing and presentation pathway. J.
Immunol. 175, 1047−1055.
(66) Warren, A., Le Couteur, D. G., Fraser, R., Bowen, D. G.,
McCaughan, G. W., and Bertolino, P. (2006) T lymphocytes interact
with hepatocytes through fenestrations in murine liver sinusoidal
endothelial cells. Hepatology 44, 1182−1190.
(67) Poulsen, K. L., Olivero-Verbel, J., Beggs, K. M., Ganey, P. E., and
Roth, R. A. (2014) Trovafloxacin enhances lipopolysaccharide-
stimulated production of tumor necrosis factor-α by macrophages:
role of the DNA damage response. J. Pharmacol. Exp. Ther. 350, 164−
170.
(68) Kakisaka, K., and Takikawa, Y. (2014) Elevation of serum
cytokines preceding elevation of liver enzymes in a case of drug-induced
liver injury. Hepatol. Res. 44, E284−289.
(69) Goto, S., Deguchi, J., Nishio, N., Nomura, N., and Funabashi, H.
(2015) Hepatotoxicants induce cytokine imbalance in response to
innate immune system. J. Toxicol. Sci. 40, 389−404.
(70) Schroder, K., Hertzog, P. J., Ravasi, T., and Hume, D. A. (2004)
Interferon-γ: an overview of signals, mechanisms and functions. J.
Leukocyte Biol. 75, 163−189.
(71) Roth, R. A., Maiuri, A. R., and Ganey, P. E. (2017) Idiosyncratic
Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?
J. Pharmacol. Exp. Ther. 360, 368−377.
(72) Steuerwald, N. M., Foureau, D. M., Norton, H. J., Zhou, J.,
Parsons, J. C., Chalasani, N., Fontana, R. J., Watkins, P. B., Lee, W. M.,
Reddy, K. R., Stolz, A., Talwalkar, J., Davern, T., Saha, D., Bell, L. N.,
Barnhart, H., Gu, J., Serrano, J., and Bonkovsky, H. L. (2013) Profiles of
serum cytokines in acute drug-induced liver injury and their prognostic
significance. PLoS One 8, e81974.
(73) Xie, Z., Chen, E., Ouyang, X., Xu, X., Ma, S., Ji, F., Wu, D., Zhang,
S., Zhao, Y., and Li, L. (2019) Metabolomics and Cytokine Analysis for
Identification of Severe Drug-Induced Liver Injury. J. Proteome Res. 18,
2514−2524.
(74) Bourdi, M., Eiras, D. P., Holt, M. P., Webster, M. R., Reilly, T. P.,
Welch, K. D., and Pohl, L. R. (2007) Role of IL-6 in an IL-10 and IL-4
double knockout mouse model uniquely susceptible to acetaminophen-
induced liver injury. Chem. Res. Toxicol. 20, 208−216.
(75) Rutz, S., Eidenschenk, C., and Ouyang, W. (2013) IL-22, not
simply a Th17 cytokine. Immunol Rev. 252, 116−132.
(76) Pan, C. X., Tang, J., Wang, X. Y., Wu, F. R., Ge, J. F., and Chen, F.
H. (2014) Role of interleukin-22 in liver diseases. Inflammation Res. 63,
519−525.
(77) Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T., Niimi, T.,
Umemura, A., Fujii, H., Okanoue, T., and Yoshikawa, T. (2011)
Blockade of IL-6 signaling exacerbates liver injury and suppresses
antiapoptotic gene expression in methionine choline-deficient diet-fed
db/db mice. Lab. Invest. 91, 609−618.
(78) Klein, C., Wustefeld, T., Assmus, U., Roskams, T., Rose-John, S.,
Muller, M., Manns, M. P., Ernst, M., and Trautwein, C. (2005) The IL-
6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T
cell-mediated liver injury. J. Clin. Invest. 115, 860−869.
(79) Coutant, D. E., and Hall, S. D. (2018) Disease-Drug Interactions
in Inflammatory States via Effects on CYP-Mediated Drug Clearance. J.
Clin. Pharmacol. 58, 849−863.
(80) Aitken, A. E., Richardson, T. A., and Morgan, E. T. (2006)
Regulation of drug-metabolizing enzymes and transporters in
inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123−149.
(81) Abdel-Razzak, Z., Loyer, P., Fautrel, A., Gautier, J. C., Corcos, L.,
Turlin, B., Beaune, P., and Guillouzo, A. (1993) Cytokines down-
regulate expression of major cytochrome P-450 enzymes in adult
human hepatocytes in primary culture. Mol. Pharmacol. 44, 707−715.
(82) Mimche, S. M., Nyagode, B. A., Merrell, M. D., Lee, C. M.,
Prasanphanich, N. S., Cummings, R. D., and Morgan, E. T. (2014)
Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are
downregulated in a Th2 environment during Schistosoma mansoni
infection. Drug Metab. Dispos. 42, 134−140.
(83) Pachkoria, K., Lucena, M. I., Crespo, E., Ruiz-Cabello, F., Lopez-
Ortega, S., Fernandez, M. A., Romero-Gomez, M., Madrazo, A., Duran,
J. A., de Dios, A. M., Borraz, Y., Navarro, J. M., and Andrade, R. J.
(2008) Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-
induced liver injury (DILI) and its outcome. J. Hepatol. 49, 107−114.
(84) Li, J., Zhu, X., Liu, F., Cai, P., Sanders, C., Lee, W. M., and
Uetrecht, J. (2010) Cytokine and autoantibody patterns in acute liver
failure. J. Immunotoxicol. 7, 157−164.
(85) Zimmermann, H. W., and Tacke, F. (2011) Modification of
chemokine pathways and immune cell infiltration as a novel therapeutic
approach in liver inflammation and fibrosis. Inflammation Allergy: Drug
Targets 10, 509−536.
(86) Charo, I. F., and Ransohoff, R. M. (2006) The many roles of
chemokines and chemokine receptors in inflammation. N. Engl. J. Med.
354, 610−621.
(87) Zlotnik, A., and Yoshie, O. (2000) Chemokines: a new
classification system and their role in immunity. Immunity 12, 121−127.
(88) Borchers, A. T., Shimoda, S., Bowlus, C., Keen, C. L., and
Gershwin, M. E. (2009) Lymphocyte recruitment and homing to the
liver in primary biliary cirrhosis and primary sclerosing cholangitis.
Semin. Immunopathol. 31, 309−322.
(89) Eksteen, B., Grant, A. J., Miles, A., Curbishley, S. M., Lalor, P. F.,
Hubscher, S. G., Briskin, M., Salmon, M., and Adams, D. H. (2004)
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
N
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-
homing lymphocytes to the liver in primary sclerosing cholangitis. J.
Exp. Med. 200, 1511−1517.
(90) Grant, A. J., Goddard, S., Ahmed-Choudhury, J., Reynolds, G.,
Jackson, D. G., Briskin, M., Wu, L., Hubscher, S. G., and Adams, D. H.
(2002) Hepatic expression of secondary lymphoid chemokine
(CCL21) promotes the development of portal-associated lymphoid
tissue in chronic inflammatory liver disease. Am. J. Pathol. 160, 1445−
1455.
(91) Moreno, C., Gustot, T., Nicaise, C., Quertinmont, E., Nagy, N.,
Parmentier, M., Le Moine, O., Deviere, J., and Louis, H. (2005) CCR5
deficiency exacerbates T-cell-mediated hepatitis in mice.Hepatology 42,
854−862.
(92) Tuncer, C., Oo, Y. H., Murphy, N., Adams, D. H., and Lalor, P. F.
(2013) The regulation of T-cell recruitment to the human liver during
acute liver failure. Liver Int. 33, 852−863.
(93) Ajuebor, M. N., Hogaboam, C. M., Le, T., Proudfoot, A. E., and
Swain, M. G. (2004) CCL3/MIP-1α is pro-inflammatory in murine T
cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells
to the liver. Eur. J. Immunol. 34, 2907−2918.
(94) Ando, K., Guidotti, L. G., Cerny, A., Ishikawa, T., and Chisari, F.
V. (1994) CTL access to tissue antigen is restricted in vivo. J. Immunol
153, 482−488.
(95) Guidotti, L. G., Inverso, D., Sironi, L., Di Lucia, P., Fioravanti, J.,
Ganzer, L., Fiocchi, A., Vacca, M., Aiolfi, R., Sammicheli, S., Mainetti,
M., Cataudella, T., Raimondi, A., Gonzalez-Aseguinolaza, G., Protzer,
U., Ruggeri, Z. M., Chisari, F. V., Isogawa, M., Sitia, G., and Iannacone,
M. (2015) Immunosurveillance of the liver by intravascular effector
CD8(+) T cells. Cell 161, 486−500.
(96) Holz, L. E., Benseler, V., Bowen, D. G., Bouillet, P., Strasser, A.,
O’Reilly, L., d’Avigdor, W. M., Bishop, A. G., McCaughan, G. W., and
Bertolino, P. (2008) Intrahepatic murine CD8 T-cell activation
associates with a distinct phenotype leading to Bim-dependent death.
Gastroenterology 135, 989−997.
(97) Kennedy, N. J., Russell, J. Q., Michail, N., and Budd, R. C. (2001)
Liver damage by infiltrating CD8+ T cells is Fas dependent. J. Immunol.
167, 6654−6662.
(98) Benechet, A. P., and Iannacone, M. (2017) Determinants of
hepatic effector CD8(+) T cell dynamics. J. Hepatol. 66, 228−233.
(99) Calne, R. Y., Sells, R. A., Pena, J. R., Davis, D. R., Millard, P. R.,
Herbertson, B. M., Binns, R. M., and Davies, D. A. (1969) Induction of
immunological tolerance by porcine liver allografts. Nature 223, 472−
476.
(100) de la Garza, R. G., Sarobe, P., Merino, J., Lasarte, J. J., D’Avola,
D., Belsue, V., Delgado, J. A., Silva, L., Inarrairaegui,M., Sangro, B., Sola,
J. J., Pardo, F., Quiroga, J., and Herrero, J. I. (2013) Trial of complete
weaning from immunosuppression for liver transplant recipients:
factors predictive of tolerance. Liver Transpl 19, 937−944.
(101) Reyes, J., Zeevi, A., Ramos, H., Tzakis, A., Todo, S., Demetris, A.
J., Nour, B., Nalesnik, M., Trucco, M., Abu-Elmagd, K., et al. (1993)
Frequent achievement of a drug-free state after orthotopic liver
transplantation. Transplant Proc. 25, 3315−3319.
(102) Knolle, P. A., and Gerken, G. (2000) Local control of the
immune response in the liver. Immunol. Rev. 174, 21−34.
(103) Tay, S. S., Wong, Y. C., McDonald, D. M., Wood, N. A.,
Roediger, B., Sierro, F., McGuffog, C., Alexander, I. E., Bishop, G. A.,
Gamble, J. R., Weninger, W., McCaughan, G. W., Bertolino, P., and
Bowen, D. G. (2014) Antigen expression level threshold tunes the fate
of CD8 T cells during primary hepatic immune responses. Proc. Natl.
Acad. Sci. U. S. A. 111, E2540−2549.
(104) Srinivasan,M., and Frauwirth, K. A. (2009) Peripheral tolerance
in CD8+ T cells. Cytokine 46, 147−159.
(105) Benseler, V., Warren, A., Vo, M., Holz, L. E., Tay, S. S., Le
Couteur, D. G., Breen, E., Allison, A. C., van Rooijen, N., McGuffog, C.,
Schlitt, H. J., Bowen, D. G., McCaughan, G. W., and Bertolino, P.
(2011) Hepatocyte entry leads to degradation of autoreactive CD8 T
cells. Proc. Natl. Acad. Sci. U. S. A. 108, 16735−16740.
(106) Burghardt, S., Erhardt, A., Claass, B., Huber, S., Adler, G.,
Jacobs, T., Chalaris, A., Schmidt-Arras, D., Rose-John, S., Karimi, K.,
and Tiegs, G. (2013) Hepatocytes contribute to immune regulation in
the liver by activation of the Notch signaling pathway in T cells. J.
Immunol. 191, 5574−5582.
(107) Bowen, D. G., Zen, M., Holz, L., Davis, T., McCaughan, G. W.,
and Bertolino, P. (2004) The site of primary T cell activation is a
determinant of the balance between intrahepatic tolerance and
immunity. J. Clin. Invest. 114, 701−712.
(108) Crispe, I. N. (2011) Liver antigen-presenting cells. J. Hepatol.
54, 357−365.
(109) Mehrfeld, C., Zenner, S., Kornek, M., and Lukacs-Kornek, V.
(2018) The Contribution of Non-Professional Antigen-Presenting
Cells to Immunity and Tolerance in the Liver. Front Immunol 9, 635.
(110) You, Q., Cheng, L., Kedl, R. M., and Ju, C. (2008) Mechanism
of T cell tolerance induction by murine hepatic Kupffer cells.
Hepatology 48, 978−990.
(111) Wan, J., Benkdane, M., Teixeira-Clerc, F., Bonnafous, S.,
Louvet, A., Lafdil, F., Pecker, F., Tran, A., Gual, P., Mallat, A.,
Lotersztajn, S., and Pavoine, C. (2014) M2 Kupffer cells promote M1
Kupffer cell apoptosis: a protective mechanism against alcoholic and
nonalcoholic fatty liver disease. Hepatology 59, 130−142.
(112) Said, E. A., Al-Reesi, I., Al-Riyami, M., Al-Naamani, K., Al-
Sinawi, S., Al-Balushi, M. S., Koh, C. Y., Al-Busaidi, J. Z., Idris, M. A.,
and Al-Jabri, A. A. (2016) Increased CD86 but Not CD80 and PD-L1
Expression on Liver CD68+ Cells during Chronic HBV Infection. PLoS
One 11, e0158265.
(113) von Oppen, N., Schurich, A., Hegenbarth, S., Stabenow, D.,
Tolba, R., Weiskirchen, R., Geerts, A., Kolanus, W., Knolle, P., and
Diehl, L. (2009) Systemic antigen cross-presented by liver sinusoidal
endothelial cells induces liver-specific CD8 T-cell retention and
tolerization. Hepatology 49, 1664−1672.
(114) Carambia, A., Frenzel, C., Bruns, O. T., Schwinge, D., Reimer,
R., Hohenberg, H., Huber, S., Tiegs, G., Schramm, C., Lohse, A.W., and
Herkel, J. (2013) Inhibition of inflammatory CD4 T cell activity by
murine liver sinusoidal endothelial cells. J. Hepatol. 58, 112−118.
(115) Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz,
A., Huber, S., Wraith, D. C., Korn, T., Schramm, C., Lohse, A. W.,
Heeren, J., and Herkel, J. (2014) TGF-beta-dependent induction of
CD4(+)CD25(+)Foxp3(+) Tregs by liver sinusoidal endothelial cells.
J. Hepatol. 61, 594−599.
(116) Najar, M., Fayyad-Kazan, H., Faour, W. H., El Taghdouini, A.,
Raicevic, G., Najimi, M., Toungouz, M., van Grunsven, L. A., Sokal, E.,
and Lagneaux, L. (2017) Human hepatic stellate cells and
inflammation: A regulated cytokine network balance. Cytokine 90,
130−134.
(117) Charles, R., Chou, H. S.,Wang, L., Fung, J. J., Lu, L., andQian, S.
(2013) Human hepatic stellate cells inhibit T-cell response through B7-
H1 pathway. Transplantation 96, 17−24.
(118) Schildberg, F. A., Wojtalla, A., Siegmund, S. V., Endl, E., Diehl,
L., Abdullah, Z., Kurts, C., and Knolle, P. A. (2011) Murine hepatic
stellate cells veto CD8 T cell activation by a CD54-dependent
mechanism. Hepatology 54, 262−272.
(119) Dunham, R. M., Thapa, M., Velazquez, V. M., Elrod, E. J.,
Denning, T. L., Pulendran, B., and Grakoui, A. (2013) Hepatic stellate
cells preferentially induce Foxp3+ regulatory T cells by production of
retinoic acid. J. Immunol. 190, 2009−2016.
(120) Xia, S., Guo, Z., Xu, X., Yi, H., Wang, Q., and Cao, X. (2008)
Hepatic microenvironment programs hematopoietic progenitor differ-
entiation into regulatory dendritic cells, maintaining liver tolerance.
Blood 112, 3175−3185.
(121) Ito, T., Yang, M., Wang, Y. H., Lande, R., Gregorio, J., Perng, O.
A., Qin, X. F., Liu, Y. J., and Gilliet, M. (2007) Plasmacytoid dendritic
cells prime IL-10-producing T regulatory cells by inducible
costimulator ligand. J. Exp. Med. 204, 105−115.
(122) Castellaneta, A., Sumpter, T. L., Chen, L., Tokita, D., and
Thomson, A. W. (2009) NOD2 ligation subverts IFN-α production by
liver plasmacytoid dendritic cells and inhibits their T cell
allostimulatory activity via B7-H1 up-regulation. J. Immunol. 183,
6922−6932.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
O
(123) Bjornsson, E. S. (2016) Hepatotoxicity by Drugs: The Most
Common Implicated Agents. Int. J. Mol. Sci. 17, 224.
(124) DeMartin, E., Michot, J. M., Papouin, B., Champiat, S., Mateus,
C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S.,
Robert, C., Marabelle, A., Guettier, C., and Samuel, D. (2018)
Characterization of liver injury induced by cancer immunotherapy
using immune checkpoint inhibitors. J. Hepatol. 68, 1181−1190.
(125) Metushi, I. G., Hayes, M. A., and Uetrecht, J. (2015) Treatment
of PD-1(−/−) mice with amodiaquine and anti-CTLA4 leads to liver
injury similar to idiosyncratic liver injury in patients. Hepatology 61,
1332−1342.
(126) Pettinato, G., Lehoux, S., Ramanathan, R., Salem, M. M., He, L.
X., Muse, O., Flaumenhaft, R., Thompson, M. T., Rouse, E. A.,
Cummings, R. D., Wen, X., and Fisher, R. A. (2019) Generation of fully
functional hepatocyte-like organoids from human induced pluripotent
stem cells mixed with Endothelial Cells. Sci. Rep 9, 8920.
(127) Augustyniak, J., Bertero, A., Coccini, T., Baderna, D., Buzanska,
L., and Caloni, F. (2019) Organoids are promising tools for species-
specific in vitro toxicological studies. J. Appl. Toxicol., DOI: 10.1002/
jat.3815.
(128) Susukida, T., Aoki, S., Kogo, K., Fujimori, S., Song, B., Liu, C.,
Sekine, S., and Ito, K. (2018) Evaluation of immune-mediated
idiosyncratic drug toxicity using chimeric HLA transgenic mice. Arch.
Toxicol. 92, 1177−1188.
(129) Cardone, M., Garcia, K., Tilahun, M. E., Boyd, L. F.,
Gebreyohannes, S., Yano, M., Roderiquez, G., Akue, A. D., Juengst,
L., Mattson, E., Ananthula, S., Natarajan, K., Puig, M., Margulies, D. H.,
and Norcross, M. A. (2018) A transgenic mouse model for HLA-
B*57:01-linked abacavir drug tolerance and reactivity. J. Clin. Invest.
128, 2819−2832.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.9b00275
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
P
